Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The other big challenge is, despite having ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. This is an exciting time to think about ...

Significantly more patients with moderately to severely active ulcerative colitis achieved clinical remission with the investigational monoclonal antibody tulisokibart compared with placebo, a ...

However, they feel their findings provide a deeper understanding of IBDs and offer a way in which ulcerative colitis could be treated. “Our results indicate the relocation of bacteria from the mouth ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody tulisokibart continued to maintain clinical and endoscopic improvements through week ...

MRM Health has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) ...

To induce remission in active, mild-to-moderate ulcerative colitis. Mesalamine is an anti-inflammatory agent that is commonly used as a treatment for the induction of remission in patients with ...